Vanda Pharmaceuticals, Anaptys to Develop and Commercialize Imsidolimab in GPP
Vanda Pharmaceuticals Inc. and AnaptysBio, Inc. are partnering to develop and commercialize imsidolimab (interleukein [IL]-36R antagonist mAb), which has successfully completed two registration-enabling global Phase 3 trials, GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of imsidolimab in patients with Generalized Pustular Psoriasis (GPP). Imsidolimab inhibits the function of the IL-36R, compensating for the deficiency […]